Abstract 2792
Background
Patient education is quite a current notion that has proved its efficiency. It has been shown as discussed in previous sections that it improves quite significantly treatment outcomes. Through education and support programs, patients health literacy is improved and so is the adherence of treatment. In this light, an education and support program was adapted at the Mohamed VI center for cancer treatment in Casablanca, with the following objectives: 1. Improve patient’s adherence to treatment 2. Increase early detection of chemotherapy side effects between cures 3. Improve quality of life and avoid toxic deaths.
Methods
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated.
Results
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated. 86,5% of the respondents were female while 13,5% were male. Of this, 70,8 % were literate while 29,2% were illetrate. Most of them, 57,2% had some awareness about cancer before they were included into the program while the rest , 42,8% had no cancer awareness. Most of the patients, 86,5% found that the videos and flyers were easy to understand while 80,2% reported that the same was helpful. 76% of the respondents admitted that the program had helped them become more proactive in their treatment. 78,1% of them were satisfied with the mobile phone calls in managing their complications at home without necessaroly coming to the hospital. 99% of the patients said that they would likely recommend the program to other patients. In overall, 87,5% of the patients were satisfied with the education program while only 3,1 % were dissatisfied. The rest of the respondents, 9,3% were neither satisfied nor dissatisfied.
Conclusions
At the end of the study, our findings were generally comparable to those in the literature and all the indicators were achieved. Therefore, this pilot program should be fully implemented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract